Aigen Investment Management LP Takes $128,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Aigen Investment Management LP bought a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in the 1st quarter, HoldingsChannel.com reports. The firm bought 16,159 shares of the biopharmaceutical company’s stock, valued at approximately $128,000.

Several other hedge funds have also modified their holdings of SAGE. Caligan Partners LP purchased a new stake in shares of Sage Therapeutics during the fourth quarter valued at $16,575,000. Boothbay Fund Management LLC acquired a new position in Sage Therapeutics during the fourth quarter valued at $7,540,000. Monaco Asset Management SAM acquired a new position in Sage Therapeutics during the first quarter valued at $3,511,000. Vanguard Group Inc. raised its position in Sage Therapeutics by 4.9% during the first quarter. Vanguard Group Inc. now owns 5,077,288 shares of the biopharmaceutical company’s stock valued at $40,364,000 after buying an additional 239,119 shares during the period. Finally, Jane Street Group LLC raised its position in Sage Therapeutics by 103.1% during the fourth quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company’s stock valued at $2,509,000 after buying an additional 234,528 shares during the period. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Price Performance

Shares of SAGE stock opened at $8.68 on Friday. The firm has a market cap of $543.54 million, a P/E ratio of -1.78 and a beta of 0.26. The stock’s 50-day moving average is $8.75 and its two-hundred day moving average is $7.77. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $11.44.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Wednesday, July 30th. The biopharmaceutical company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.17. The business had revenue of $31.66 million for the quarter, compared to analyst estimates of $16.69 million. Sage Therapeutics had a negative return on equity of 67.10% and a negative net margin of 427.78%. The firm’s revenue for the quarter was up 266.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.70) EPS. As a group, research analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on SAGE. Scotiabank lowered Sage Therapeutics from a “strong-buy” rating to a “hold” rating and dropped their price target for the company from $12.00 to $9.20 in a research report on Tuesday, July 8th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research report on Monday, June 16th. Wall Street Zen raised Sage Therapeutics to a “hold” rating in a research report on Saturday, August 2nd. Robert W. Baird upped their price target on Sage Therapeutics from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, June 20th. Finally, Truist Financial set a $9.00 price target on Sage Therapeutics and gave the company a “hold” rating in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating and fourteen have issued a hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.85.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.